Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lawrence Fong

Showing results (1-10 of 198) with videos related to

Pageof 20
Sort By:
Oncology (Williston Park, N.Y.)|March 17, 2018
Immunotherapy for Prostate Cancer: Where Do We Go From Here?-PART 1: Prostate Cancer VaccinesAmar Patel, Lawrence Fong
Oncology (Williston Park, N.Y.)|June 26, 2018
Immunotherapy for Prostate Cancer: Where Do We Go From Here?-PART 2: Checkpoint Inhibitors, Immunotherapy Combinations, Tumor Microenvironment Modulation, and Cellular TherapiesAmar Patel, Lawrence Fong
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 6, 2005
CTLA-4 blockade: autoimmunity as treatmentDilnawaz Kapadia, Lawrence Fong
Prostate Cancer and Prostatic Diseases|April 6, 2021
How to turn up the heat on the cold immune microenvironment of metastatic prostate cancerJacob Stultz, Lawrence Fong
Current Opinion in Molecular Therapeutics|February 9, 2010
Therapeutic vaccines for prostate cancerEdward Cha, Lawrence Fong
Oncoimmunology|April 11, 2018
Shuffling the deck with CTLA-4 therapy: Deep sequencing of rearranged TCRB genes demonstrates T cell repertoire remodeling in cancer patientsEdward Cha, Lawrence Fong
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 10, 2011
Immunotherapy for prostate cancer: biology and therapeutic approachesEdward Cha, Lawrence Fong
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 31, 2016
Can Prostate Cancer Really Respond to Immunotherapy?Won Kim, Lawrence Fong
The Journal of Experimental Medicine|August 7, 2025
CD4+ T cell dysfunction in cancerHrishi Venkatesh, Lawrence Fong
Trends in Cancer|August 6, 2023
CD4<sup>+</sup> T cells help myeloid-mediated killing of immune-evasive tumorsKai Wu, Lawrence Fong
Pageof 20

Showing results (1-10 of 198) with videos related to

Sort By:
Pageof 20
Oncology (Williston Park, N.Y.)|March 17, 2018
Immunotherapy for Prostate Cancer: Where Do We Go From Here?-PART 1: Prostate Cancer VaccinesAmar Patel, Lawrence Fong
Oncology (Williston Park, N.Y.)|June 26, 2018
Immunotherapy for Prostate Cancer: Where Do We Go From Here?-PART 2: Checkpoint Inhibitors, Immunotherapy Combinations, Tumor Microenvironment Modulation, and Cellular TherapiesAmar Patel, Lawrence Fong
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 6, 2005
CTLA-4 blockade: autoimmunity as treatmentDilnawaz Kapadia, Lawrence Fong
Prostate Cancer and Prostatic Diseases|April 6, 2021
How to turn up the heat on the cold immune microenvironment of metastatic prostate cancerJacob Stultz, Lawrence Fong
Current Opinion in Molecular Therapeutics|February 9, 2010
Therapeutic vaccines for prostate cancerEdward Cha, Lawrence Fong
Oncoimmunology|April 11, 2018
Shuffling the deck with CTLA-4 therapy: Deep sequencing of rearranged TCRB genes demonstrates T cell repertoire remodeling in cancer patientsEdward Cha, Lawrence Fong
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 10, 2011
Immunotherapy for prostate cancer: biology and therapeutic approachesEdward Cha, Lawrence Fong
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 31, 2016
Can Prostate Cancer Really Respond to Immunotherapy?Won Kim, Lawrence Fong
The Journal of Experimental Medicine|August 7, 2025
CD4+ T cell dysfunction in cancerHrishi Venkatesh, Lawrence Fong
Trends in Cancer|August 6, 2023
CD4<sup>+</sup> T cells help myeloid-mediated killing of immune-evasive tumorsKai Wu, Lawrence Fong
Pageof 20